共 18 条
[1]
Alzheimer’s disease and the glutamate NM- DA receptor. DORAISWAMY PM. Psychopharmacologia . 2003
[2]
Memantine:A phar- macoeconomic review of its use in moderate-to-severe Alzheimer’s Disease. PLOSKER GL,LYSENG-WILLIAMSON KA. Pharmacoeconomics . 2005
[3]
Alzheimer’s disease:genes,proteins,and therapy. DENNIS JS. Physiological Reviews . 2001
[4]
Memantine. KILPATRICK GJ,TILBROOK GS. Merz Curr Opin Investig Drugs . 2002
[5]
The neuro- protective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain. MARVANOVA M,LAKSO M,PIRHONEN J,et al. Molecular and Cellular Neurosciences . 2001
[6]
Lack of pharmacokinetic or pharmacodynamlc interaction between me- mantine and donepezil. PERICLOU AP,VENTURA D,SHERMAN T,et al. International Journal of Geriatric Psychiatry . 2004
[7]
Evaluation of memantine for neuroprotection in demen- tia. JAIN KK. Expert Opinion on Investigational Drugs . 2000
[8]
Long-term treat- ment with the NMDA antagonist memantine:results of a 24- week,open-label extensioe study in moderately severe-to-severe Alzheimer’s disease. REISBEPG B,FERRIS S,M(?)BIUS HJ,et al. Neurobiology of Aging . 2002
[9]
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil:a randomized controlled trial. TARIOT PN,FARLOW MR,GROSSBERG GT. The Journal of The American Medical Association . 2004
[10]
Memantine is a clini- cally well tulerated N-methyl-d-aspartate (NMDA) receptor an- tagonist-a review of preclinical data. PARSONS CG,DANYSZ W,QUACK G. Neuropharmacology . 1999